SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Exclusion Criteria

• •1. Subjects with any active autoimmune disease or history of autoimmune disease;
• •2. Subjects having clinical symptoms of metastases to central nervous system (such as cerebral edema, requiring steroids intervention, or brain metastasis progression);
• •3. Has a known additional malignancy within the last 5 years before study treatment with the exception of curatively treated basal cell and squamous cell carcinoma of the skin and/or curatively resected in-situ cervical and/or breast cancers;
• •4. Uncontrolled clinically significant heart disease, including but not limited to the following: (1) \> NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;
• •5. Concurrent medical condition requiring the use of cortisol (\>10mg/day Prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment. Except: inhalation or topical corticosteroids. Doses \> 10 mg/day prednisone or equivalent for replacement therapy;
• •6. Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy within 4 weeks prior to first dosing or not recovered to ≤CTCAE 1 from adverse events (except for hair loss or neurotoxic sequelae from prior platinum therapy) due to a previously administered agent. Palliative irradiation should be ended 2 weeks before first dosing;
• •7. Active infection or an unexplained fever \> 38.5°C before two weeks of first dosing (subjects with tumor fever may be enrolled at the discretion of the investigator);
• •8. Known Human Immunodeficiency Virus (HIV) infection、active Hepatitis B or Hepatitis C;
• •9. Currently participating or has participated in a study within 4 weeks of the first dose of study medication;
• •10. Received a live vaccine within 4 weeks of the first dose of study medication. Pregnancy or breast feeding;
• •11. Received a systematic antibiotics within 4 weeks of the first dose of study medication.
• •Pregnancy or breast feeding.
• •12. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent;
• •13. Subjects are known to have a history of psychiatric substance abuse, alcoholism, or drug addiction;
• •14. Pregnancy or breast feeding;
• •15. According to the investigator, other conditions that may lead to stop the research.